Stephan A. Grupp

TL;DR: The T-cell distribution from children with solid tumors and lymphomas at diagnosis and after every cycle of chemotherapy was investigated, finding that patients with T cells enriched for naïve and stem central memory cells expanded well in vitro, but the majority of tumor types showed chemotherapy-related depletion of early lineage cells with a corresponding decline in successful ex vivo stimulation response.

TL;DR: Responsibility to tisagenlecleucel was associated with increased expansion across a wide dose range and the importance of cellular kinetics in understanding determinants of response to chimeric antigen receptor T-cell therapy is highlighted.

TL;DR: Time-course studies demonstrated that durable leukemia remission required CAR T-cell persistence for 4 weeks prior to ablation, and demonstrated successful hematopoietic engraftment with a normal human donor to model allogeneic stem cell rescue.

TL;DR: Fractionated dosing of CTL019 with intrapatient dose modification optimizes safety without compromising efficacy in adults with r/r ALL.

TL;DR: A targeted approach is developed that targets IL-6, a key cytokine in the toxicity response, using theIL-6 receptor antagonist tocilizumab, which has the potential to control toxicity while maintaining efficacy.